Digoxin v placebo for heart failure (HF) in men and women‡
| Outcomes at ≤48 months | Sex | Digitalis | Placebo | Adjusted RRR (95% CI) | Adjusted NNT (CI) |
|---|---|---|---|---|---|
| All cause mortality | Men | 35.2% | 36.9% | 6% (−2 to 12) | Not significant |
| Cardiovascular death | 30.5% | 31.1% | 3% (−5 to 11) | Not significant | |
| Death from worsening HF | 11.4% | 13.6% | 20% (7 to 30) | 38 (25 to 99) | |
| Hospital admission for worsening HF | 25.8% | 34.7% | 29% (23 to 35) | 10 (9 to 13) |
| Adjusted RRI (CI) | Adjusted NNH (CI) | ||||
|---|---|---|---|---|---|
| Hospital admission for other causes | 39.9% | 35.0% | 13% (6 to 21) | 22 (14 to 52) | |
| All cause mortality | Women | 33.1% | 28.9% | 19% (2 to 36) | 19 (10 to 207) |
| Cardiovascular death | 27.8% | 24.1% | 20% (2 to 42) | 21 (10 to 240) | |
| Death from worsening HF | 12.4% | 11.9% | 16% (−12 to 51) | Not significant | |
| Hospital admission for other causes | 35.9% | 32.2% | 12% (−2 to 28) | Not significant |
| Adjusted RRR (CI) | Adjusted NNT | ||||
|---|---|---|---|---|---|
| ‡Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from control event rates and adjusted hazard ratios in article. | |||||
| Hospital admission for worsening HF | 30.2% | 34.4% | 11 (−3 to 24) | Not significant | |